Skip to main content
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRVI ISIN · US89532M1018 US Manufacturing
Open in API
Filings indexed 505 across all filing types
Latest filing 2023-06-14 Director's Dealing
Country US United States of America
Listing US TRVI

About Trevi Therapeutics, Inc.

https://www.trevitherapeutics.com/

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of its investigational therapy, Haduvio™ (oral nalbuphine ER). The company's primary program is aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). These conditions represent a significant unmet medical need with no approved therapies in the United States. Haduvio is a dual-mechanism therapy that acts as a kappa opioid receptor agonist and a mu opioid receptor antagonist, targeting both central and peripheral nerve pathways believed to cause chronic cough. The company has reported positive results from its Phase 2b CORAL trial in IPF chronic cough and its Phase 2a RIVER trial in refractory chronic cough.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-06-14 English
Regulatory Filings 2023
Regulatory Filings
2023-06-12 English
FORM 4 SUBMISSION
Director's Dealing
2023-05-15 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities under employee benefit plans such as stock incentive plans and employee stock purchase plans. It includes details about the plans, incorporation by reference to previous filings, exhibits, and signatures of officers and directors. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication notice.
2023-05-11 English
10-Q
Interim / Quarterly Report Q1 2023
2023-05-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2023, by Trevi Therapeutics, Inc. It announces the company's financial results for the quarter and year ended March 31, 2023. The text states that the full press release with the financial results is furnished as an exhibit and incorporated by reference, but the 8-K itself does not contain detailed financial statements or substantive financial data. The document is short (3,678 characters) and primarily serves as an announcement of the earnings release rather than the earnings release itself. According to the rules, such announcements are classified as Regulatory Filings (RNS) because the actual financial data is in the press release exhibit, not in the 8-K text provided. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-05-11 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.